Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095434 | 0.90 | KDM4E (0.39) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL10095291 | 0.88 | L3MBTL1 (0.46) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL981984 | 0.87 | PGR (0.43) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL982317 | 0.87 | KDM4E (0.39) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL982903 | 0.85 | PFKFB1 (0.44) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL981436 | 0.85 | MAPT (0.38) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL10095322 | 0.85 | PFKFB2 (0.47) | KDM4EMAPTMEN1KMT2ARAB9A | |
| SCHEMBL10095295 | 0.84 | KDM4E (0.44) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL10095361 | 0.84 | MAPT (0.44) | KDM4EMAPTMEN1KMT2ALMNA | |
| SCHEMBL10095377 | 0.84 | PFKFB2 (0.55) | KDM4EMAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1984332-A2 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1979315-A2 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | KDM4E 433/4885MAPT 3963/4885MEN1 4550/4885 |
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KDM4E 4020/4885MAPT 4477/4885MEN1 4800/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | KDM4E 3422/4885MAPT 3547/4885MEN1 4825/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | KDM4E 3703/4885MAPT 4416/4885MEN1 4815/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KDM4E 4020/4885MAPT 4477/4885MEN1 4800/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KDM4E 4020/4885MAPT 4477/4885MEN1 4800/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KDM4E 4020/4885MAPT 4477/4885MEN1 4800/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KDM4E 4020/4885MAPT 4477/4885MEN1 4800/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | KDM4E 3703/4885MAPT 4416/4885MEN1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.